All In Biotech

Drug Trial Radar · NCT01732913

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 295 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

295

Actual

Start

Jan 16, 2013

Primary completion

May 18, 2016

Study completion May 18, 2016

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Nov 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL). An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).

Conditions

  • Indolent Non-Hodgkin's Lymphomas

Interventions

  • PlaceboDrug

    Tablets administered orally twice daily

  • RituximabDrug

    375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)

  • IdelalisibDrug

    150 mg tablets administered orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival

Locations

103 sites in 19 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama

  • Ironwood Cancer and Research Center

    Chandler, Arizona

  • City of Hope Cancer Center

    Duarte, California

  • Saint Jude Heritage Healthcare

    Fullerton, California

  • Pacific Shores Medical Group

    Long Beach, California

  • UCLA Medical Center

    Los Angeles, California

  • Cancer Care Associates

    Redondo Beach, California

  • Cancer Center of Santa Barbara

    Santa Barbara, California

  • Central Coast Medical Oncology Group

    Santa Maria, California

  • Middlesex Hospital Cancer Center

    Middletown, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Florida Cancer Specialists and Research Institute

    Fort Myers, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Cancer Center of Kansas

    Wichita, Kansas

  • Wayne State University

    Detroit, Michigan

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • MetroHealth Medical Center

    Cleveland, Ohio

  • Signal Point Clinical Research Center, LLC

    Middletown, Ohio

  • Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Prairie Lakes Healthcare System

    Watertown, South Dakota

  • Tennessee Oncology, PLLC

    Chattanooga, Tennessee

  • Sarah Cannon Cancer Center

    Nashville, Tennessee

  • Texas Oncology, P.A.

    Bedford, Texas

  • Brooke Army Medical Center

    Fort Sam Houston, Texas

  • Center for Cancer and Blood Disorders, PC

    Fort Worth, Texas

  • Shenandoah Oncology Associates, PC

    Winchester, Virginia

  • Virginia Mason Medical Center

    Seattle, Washington

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington

  • Froedtert Hospital and Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Adelaide Cancer Centre

    Kurralta Park, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Haematology and Oncology Clinics of Australia at Chermside

    Milton, Queensland, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Saint Vincent's Hospital

    Fitzroy, Victoria, Australia

  • Western Hospital

    Footscray, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

Showing 40 of 103 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.